Wave Life Sciences Ltd. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This annual filing is not a standalone fourth-quarter report. Wave is a Singapore-incorporated, clinical-stage biotechnology company developing RNA medicines; it has no product sales.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Collaboration revenue | $113.3 million | $3.6 million |
| Research and development expense | $130.0 million | $115.9 million |
| General and administrative expense | $51.3 million | $50.5 million |
| Operating loss | $68.0 million | $162.7 million |
| Net loss | $57.5 million | $161.8 million |
| Net loss per ordinary share | $0.54 | $2.05 |
| Cash used in operating activities | $19.4 million | $127.8 million |
- Cash and cash equivalents were $200.4 million at year-end; restricted cash was $3.7 million. Management expected existing cash to fund operations for at least 12 months, while cautioning that actual spending could differ from assumptions.
- Net cash provided by financing was $132.5 million in 2023, primarily from the December share offering and GSK’s equity investment. Cash, cash equivalents and restricted cash totaled $204.1 million at year-end.
- No borrowings are reported in the supplied financial statements. Operating lease liabilities totaled $32.1 million; undiscounted future lease payments were $38.4 million, including $9.3 million due in 2024.
- Current assets were $235.4 million and current liabilities $186.4 million. Current liabilities include substantial deferred collaboration revenue, not just amounts payable in cash.
- Wave has an accumulated deficit of $1.025 billion and expects continuing operating losses; it has not generated product revenue. Product gross margin is therefore not applicable.
Changes versus 2022
- Revenue rose by $109.7 million, principally because the GSK collaboration became effective in January 2023 and more Takeda collaboration revenue was recognized.
- Revenue is collaboration-related, not product revenue. Of 2023 revenue, $66.3 million was under GSK and $47.0 million under Takeda.
- Net loss narrowed by $104.3 million, reflecting the revenue increase and higher other income, partly offset by $14.2 million more R&D expense. Other income rose to $9.8 million, mainly from dividend and interest income and refundable tax credits.
- Operating cash outflow declined by $108.4 million. The 2023 figure was supported by a $54.3 million increase in deferred revenue, while accounts receivable increased $21.1 million, including the GSK milestone receivable.
Programs, outlook and material items
- Pipeline: Lead programs are WVE-006 for alpha-1 antitrypsin deficiency (AATD), an INHBE-targeting obesity candidate, WVE-N531 for Duchenne muscular dystrophy (DMD), and WVE-003 for Huntington’s disease (HD).
- Stated milestones: Wave expected AATD proof-of-mechanism data in patients in 2024; WVE-N531 dystrophin data from the Phase 2 FORWARD-53 study in the third quarter of 2024; and WVE-003 data from its 30 mg multi-dose cohort and single-dose cohorts in the second quarter of 2024. The company expected to begin an INHBE clinical trial in the first quarter of 2025 and select five new clinical candidates by the end of 2025. These are management expectations, not assurances.
- GSK collaboration: GSK received an exclusive global license to WVE-006; Wave is responsible for development through the initial clinical study, after which responsibilities are expected to transfer to GSK. Wave may receive additional development, launch and commercial milestones and tiered royalties if contractual conditions are met. A $20 million WVE-006 milestone was achieved in 2023; it was recorded as a receivable at year-end and collected in the first quarter of 2024.
- Takeda collaboration and unusual revenue: Takeda terminated the C9/ALS-FTD and SCA3 targets in 2023. Those terminations led to recognition of $28.0 million and $9.9 million, respectively, of previously deferred revenue. A separate $7.0 million WVE-003 nonclinical milestone was also recognized. These items contributed to 2023 revenue and should not be mistaken for recurring product sales.
- Financing and dilution: Wave sold 20.0 million shares at $5.00 in December 2023 for $93.6 million net proceeds. Underwriters purchased another 3.0 million shares in January 2024, generating approximately $14.0 million net. GSK’s 2023 equity investment generated $34.6 million net proceeds. Shares outstanding were 119.2 million at year-end and 122.3 million on February 28, 2024.
- Key risks: Clinical and regulatory outcomes remain uncertain; early results may not predict later trials. The company requires substantial future funding and may face dilution or unfavorable financing terms. It also cites manufacturing and supply-chain constraints, competition, reliance on collaborators and third parties, intellectual-property risks, and potential delays in patient enrollment.
- Other disclosures: Wave is assessing potential Singapore patent-filing compliance issues involving approximately 140 applications; the filing says the authority’s decision was pending and potential penalties are uncertain. A cybersecurity incident at an assay vendor did not affect Wave data or samples and had no material financial impact. Wave reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether the company met the 2024 clinical-data milestones and whether findings support further development, particularly WVE-006 proof of mechanism and WVE-N531 dystrophin expression.
- How much of collaboration revenue and cash flow reflects nonrecurring milestones, terminated programs, or upfront funding, and the expected timing of recognition of remaining deferred revenue.
- Cash use, collaboration receipts, and updated runway after the January 2024 offering; whether additional financing is required and its dilution impact.
- Progress and terms under the GSK and Takeda agreements, including partner options, future milestone conditions, royalties, and any program changes.
- The status and consequences of the Singapore patent-filing matter, as well as the potential impact of manufacturing, clinical, regulatory, and intellectual-property risks.